Avacta secures £12.5m as cancer drug pipeline hits key milestones
The AIM-listed company has raised the money through a placing and subscription of new shares at 68p each, giving it funding to extend its cash runway into the second quarter of 2027
The AIM-listed company has raised the money through a placing and subscription of new shares at 68p each, giving it funding to extend its cash runway into the second quarter of 2027
